LIPOPROTEINLAR

Tashpo’latov To’lqin Aliyarovich; Jabborova Gulbaxor Rashid qizi

Authors

Tashpo’latov To’lqin Aliyarovich Author
Jabborova Gulbaxor Rashid qizi Author

Abstract

Ushbu maqolada lipoproteinlarning tuzilishi, sinflari, biologik vazifalari va ularning lipid almashinuviga ta’siri ilmiy manbalar asosida yoritildi. Tadqiqot lipoproteinlarning asosiy komponentlari — apolipoproteinlar, triglitseridlar, fosfolipidlar va xolesterin efirlarining tashilish jarayonlaridagi roli va klinik ahamiyatini baholashga qaratildi. Maqolada yuqori, past va juda past zichlikdagi lipoproteinlarning metabolik yo‘llari, ularning fermentlar bilan o‘zaro ta’siri hamda ateroskleroz kabi yirik kasalliklar patogenezidagi o‘rni ilmiy asosda tahlil qilindi. Olingan natijalar lipoproteinlar muvozanatining buzilishi yurak-qon tomir kasalliklari xavfini oshirishini ko‘rsatadi. Ushbu ma’lumotlar klinik biokimyo, kardiologiya va metabolik kasalliklarni o‘rganishda muhim ilmiy asos yaratadi.

References

1. Nelson DL, Cox MM. Lehninger Principles of Biochemistry. 7th ed. New York: W.H. Freeman & Company; 2017.

2. Murray RK, Bender DA, Botham KM, Kennelly PJ, Rodwell VW. Harper's Illustrated Biochemistry. 31st ed. New York: McGraw-Hill Education; 2018.

3. Berg JM, Tymoczko JL, Stryer L. Biochemistry. 9th ed. New York: W.H. Freeman & Company; 2019.

4. Marshall WJ, Lapsley M, Day A, Ayling RM. Clinical Biochemistry: Metabolic and Clinical Aspects. 4th ed. London: Churchill Livingstone; 2014.

5. Ross MH, Pawlina W. Histology: A Text and Atlas. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2020.

6. Feingold KR, Grunfeld C. Introduction to Lipids and Lipoproteins. In: Endotext [Internet]. MDText.com, Inc.; 2022.

7. Talayero BG, Sacks FM. The role of triglycerides in atherosclerosis. Curr Cardiol Rep. 2011;13(6):544–552.

8. Libby P, Bornfeldt KE, Tall AR. Atherosclerosis: successes, surprises, and future challenges. Circ Res. 2016;118(4):531–534.

9. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Eur Heart J. 2017;38(32):2459–2472.

10. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell. 2001;104(4):503–516.

11. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Anti-inflammatory properties of HDL. Circ Res. 2004;95(8):764–772.

12. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232(4746):34–47.

13. Toth PP. Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. Vasc Health Risk Manag. 2016;12:171–183.

14. Ridker PM, Luscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J. 2014;35(27):1782–1791.